AT THIS TIME of year, scores of millions of people go to church. Even sheep who have strayed from the Lord’s flock often find their way back at Christmas. They come to hear the story of Mary, Joseph ...

WASHINGTON (AP) — President Donald Trump said Monday that he would allow Nvidia to sell an advanced type of computer chip used in the development of artificial intelligence to "approved customers" in ...

Archaeologists uncovered a basalt tablet in the Bashplemi Lake region of Georgia with an unknown language carved into its face. The tablet featured 60 characters across seven rows. Experts said that ...

Cypherpunk Technologies (CYPH), a digital-asset treasury firm backed by Gemini founders Cameron and Tyler Winklevoss, said it added $18 million worth of Zcash ZEC $368.65 to its balance sheet. The ...

REDWOOD CITY, Calif., Nov. 14, 2025 /PRNewswire/ -- Zilliz, the company behind Milvus, the world's most widely adopted open-source vector database, today forecasts a major shift in enterprise data ...

In most enterprises, data access still feels like a locked room with SQL as the only key. Business teams depend on data engineers for every report, dashboard, or metric tweak. Even in the age of ...

The Digital Credentials Query Language (DCQL) is very relevant to the EU Digital Identity Wallet (EUDI Wallet) ecosystem. As banks will start asking for verifiable credentials needed - for example in ...

Dolby unveiled Dolby Vision 2 in September, and Samsung has already fired back with its own upgrades to its image quality format. The company is a key player in the consortium behind the HDR10 and ...

Google added a very useful feature to the Google Search Console Insights report named query groups. It does what it is named, it groups similar queries together as one, so you can see how your site is ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer. Adding the drug enzalutamide to standard hormone therapy reduced the risk of ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...